<?xml version="1.0" encoding="utf-8"?>
<Document>
  <Do_id>21933750</Do_id>
  <Journal>The Lancet. Oncology</Journal>
  <Doc_title>Hope without hype: EML4-ALK inhibition for treatment of lung cancer.</Doc_title>
  <Doc_abstract>None</Doc_abstract>
  <Doc_ChemicalList>Antineoplastic Agents;Protein Kinase Inhibitors;Pyrazoles;Pyridines;crizotinib;Receptor Protein-Tyrosine Kinases;anaplastic lymphoma kinase</Doc_ChemicalList>
  <Doc_meshdescriptors>Antineoplastic Agents;Carcinoma, Non-Small-Cell Lung;Female;Gene Rearrangement;Humans;Lung Neoplasms;Male;Protein Kinase Inhibitors;Pyrazoles;Pyridines;Receptor Protein-Tyrosine Kinases</Doc_meshdescriptors>
  <Doc_meshqualifiers>therapeutic use;drug therapy;drug therapy;therapeutic use;therapeutic use;therapeutic use;antagonists &amp; inhibitors</Doc_meshqualifiers>
</Document>
